Long-Term Follow-Up After Sirolimus-Eluting Stent Implantation

Five-year results of a landmark trial confirm the benefits and safety of on-label use of SES.

The manufacturer-sponsored, randomized SIRIUS trial (JW Cardiol Nov 14 2003) was the first to document a reduction in 1-year restenosis rates with sirolimus-eluting stents (SES) compared with bare-metal stents (BMS). The lesions treated in that study informed the on-label indications for this device and were generally less complex than those treated with SES in current, real-world practice. The SIRIUS investigators now report 5-year clinical outcomes in the 1058 participants.

The relative reductions in restenosis and adverse cardiovascular events with SES versus BMS were maintained at 5 years, although all clinical endpoints gradually increased in both groups. The target-lesion revascularization rate increased in both groups by about 4% afte…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI